Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Convertible Debt: 2014-2017

Historic Convertible Debt for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2017 value amounting to $1.9 million.

  • Lineage Cell Therapeutics' Convertible Debt rose 80.72% to $1.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.9 million, marking a year-over-year increase of 80.72%. This contributed to the annual value of $1.9 million for FY2017, which is 80.72% up from last year.
  • As of FY2017, Lineage Cell Therapeutics' Convertible Debt stood at $1.9 million, which was up 80.72% from $1.0 million recorded in FY2016.
  • Lineage Cell Therapeutics' Convertible Debt's 5-year high stood at $1.9 million during FY2017, with a 5-year trough of $60,000 in FY2014.
  • Over the past 3 years, Lineage Cell Therapeutics' median Convertible Debt value was $1.0 million (recorded in 2016), while the average stood at $1.1 million.
  • Data for Lineage Cell Therapeutics' Convertible Debt shows a peak YoY skyrocketed of 440.00% (in 2015) over the last 5 years.
  • Over the past 4 years, Lineage Cell Therapeutics' Convertible Debt (Yearly) stood at $60,000 in 2014, then soared by 440.00% to $324,000 in 2015, then skyrocketed by 218.52% to $1.0 million in 2016, then surged by 80.72% to $1.9 million in 2017.